er, Really nice to meet you. The drug, an Anti-Abeta antibody (Anti-Plaues,) is the first drug in a preventive AD study and runs under the name of Crenezumab. This study is supported by NIH. There are other studies on the same molecule together with Genentech, i.e. phase 2 studies of efficacy and biomarke